Evotec Achieves Milestone in Drug Discovery Collaboration With Ono Pharmaceutical Co., Ltd.

Evotec Achieves Milestone in Drug Discovery Collaboration With Ono
Pharmaceutical Co., Ltd.

  *Evotec Receives a Milestone Payment From Ono for the Progression of a
    Compound Into Pre-Clinical Development

HAMBURG, Germany, Jan. 11, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) today announced that a compound identified and optimised in a
research collaboration with Ono Pharmaceutical Co., Ltd. ("Ono") has been
nominated to enter pre-clinical development, leading to the payment of an
agreed milestone.

This collaboration project was initiated in March 2008. Evotec combined high
throughput screening and its proprietary fragment-based drug discovery
platform to identify novel compounds active against a protease target, which
were then further optimised with Ono to generate a candidate suitable for
pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
extremely pleased that we have collaborated with Ono Pharmaceutical on this
important project and delivered a pre-clinical candidate. The teams from Ono
and Evotec have enjoyed an excellent interaction and relationship throughout
the collaboration which has helped meet this goal. This achievement clearly
demonstrates the value we bring to our alliance partners in the area of drug
discovery. We look forward to continuing working closely with our colleagues
at Ono."

"This pre-clinical candidate is an important member of our development
pipeline and we have high expectations for it. During the entire project we
could count on the access to various technologies and on the knowledge, but in
particular on the drug discovery expertise of our colleagues from Evotec. They
are an integrated part of our drug discovery strategy", said Dr Kazuhito
Kawabata, Managing Director, Research Headquarters at Ono.


Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
and with Roche in the field of Alzheimer's disease. For additional information
please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: For further information, please contact

         Dr Mario Polywka
         Chief Operating Officer
         +44.(0)1235.44 16 76
         +44.(0)1235.86 31 39 Fax
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
Press spacebar to pause and continue. Press esc to stop.